Abstract:
Hypolipidemic and anti-obesity effects of the newly synthesized indole-based fibrates were evaluated in Triton WR-1339 and HFD-induced hyperlipidemic rats. Preliminary screening of all the synthesized compounds was done by using an acute model (Triton model), in which compounds 3f and 3l showed significant antidyslipidemic activity. Furthermore, these compounds 3f and 3l were found to induce significant weight loss in the visceral fat mass of HFD-fed hyperlipidemic rats without affecting the normal feeding behavior. Histological examination of the liver of rats supplemented with 3f and 3l revealed a significant decrease in steatosis when compared to the effect of standard drug fenofibrate. Additional effects such as an increase in LCAT enzyme level and increased receptor mediated catabolism of I131-LDL confirm and reinforce the efficacy of both these compounds as a new class of dual-acting hypolipidemic and anti-obesity agents.
